Ask AI
ProCE Banner Activity

ExpressPoints
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Slideset

Download this short summary slideset of key takeaway points from a live presentation on the latest data on treatment for patients with HR+/HER2- early breast cancer.

Released: July 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Director, International Breast Cancer Center (IBCC)
Barcelona, Spain
Director, IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana
Madrid, Spain

Javier Cortes, MD, PhD: consultant/advisor: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, BioNTech, Bliss, Boehringer Ingelheim, BridgeBio, Circle, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, ExpreS2ion Biotechnologies, GEMoaB, Gilead, Hexagon, HiberCell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Relay, Reveal Genomics, Roche, Scorpion, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant, IQVIA, Merck Sharp & Dohme, Pfizer, Piqur, Roche; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; patent beneficiary: licensed patent: HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy, issued patent: pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent.

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Artios, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb/SystImmune, Celcuity, Circle, Cullinan Oncology, Daiichi Sankyo, Denali, Eisai, Genentech/Roche, Gilead, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen.